Back

A measles-vectored COVID-19 vaccine induces long-term immunity and protection from SARS-CoV-2 challenge in mice

Frantz, P. N.; Barinov, A.; Ruffie, C.; Combredet, C.; Najburg, V.; Teeravechyan, S.; Jongkaewwattana, A.; Prot, M.; Conquet, L.; Montagutelli, X.; Fernandes, P.; Strick-Marchand, H.; Di Santo, J.; Simon-Loriere, E.; Gerke, C.; Tangy, F.

2021-02-17 immunology
10.1101/2021.02.17.431630 bioRxiv
Show abstract

In light of the expanding SARS-CoV-2 pandemic, developing efficient vaccines that can provide sufficient coverage for the world population is a global health priority. The measles virus (MV)-vectored vaccine is an attractive candidate given the measles vaccines extensive safety history, well-established manufacturing process, and induction of strong, long-lasting immunity. We developed an MV-based SARS-CoV-2 vaccine using either the full-length spike (S) or S2 subunit as the antigen. While the S2 antigen failed to induce neutralizing antibodies, the prefusion-stabilized, full-length S (MV-ATU2-SF-2P-dER) construct proved to be an attractive vaccine candidate, eliciting strong Th1-dominant T-cell and neutralizing antibody responses against the S antigen while minimizing reactivity to the vector itself. Neutralizing antibody titers remained high three months after homologous prime-boost immunization, and infectious virus was undetectable in all animals after challenge with a mouse-adapted SARS-CoV-2 virus.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 9%
18.3%
Similar papers in this journal
2
npj Vaccines
○ 67 papers in training set
Top 0.1%
16.8%
Similar papers in this journal
3
PLOS Pathogens
● 820 papers in training set
Top 2%
6.6%
Similar papers in this journal
4
Frontiers in Immunology
○ 638 papers in training set
Top 2%
5.5%
Similar papers in this journal
5
Journal of Virology
● 499 papers in training set
Top 1%
4.8%
Similar papers in this journal
50% of probability mass above
6
Cell Reports
○ 1498 papers in training set
Top 11%
3.4%
7
Molecular Therapy
○ 81 papers in training set
Top 0.5%
3.4%
8
mBio
● 833 papers in training set
Top 5%
3.2%
9
iScience
○ 1154 papers in training set
Top 7%
3.2%
10
Vaccines
○ 198 papers in training set
Top 1%
2.8%
11
eLife
● 5828 papers in training set
Top 40%
2.6%
12
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 22%
2.4%
13
Scientific Reports
○ 3612 papers in training set
Top 46%
2.1%
14
Cell
○ 431 papers in training set
Top 6%
1.7%
15
eBioMedicine
○ 183 papers in training set
Top 4%
1.3%
16
Microbiology Spectrum
● 469 papers in training set
Top 9%
1.1%
17
Vaccine
○ 203 papers in training set
Top 1%
1.1%
18
Science Advances
● 1243 papers in training set
Top 26%
1.1%
19
Emerging Microbes & Infections
○ 74 papers in training set
Top 1%
1.1%
20
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.6%
1.1%
21
Science Immunology
● 88 papers in training set
Top 2%
1.0%
22
Cell Reports Medicine
○ 153 papers in training set
Top 5%
0.8%
23
Science
● 477 papers in training set
Top 9%
0.8%
24
Science Translational Medicine
● 127 papers in training set
Top 4%
0.6%
25
Cellular & Molecular Immunology
○ 14 papers in training set
Top 0.1%
0.6%
26
Nature
○ 645 papers in training set
Top 12%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.